Cancers, Vol. 13, Pages 1920: The Role of Rituximab in the Treatment of Primary Central Nervous System Lymphoma

Cancers, Vol. 13, Pages 1920: The Role of Rituximab in the Treatment of Primary Central Nervous System Lymphoma Cancers doi: 10.3390/cancers13081920 Authors: Ruben Van Dijck Jeanette K. Doorduijn Jacoline E.C. Bromberg Primary central nervous system lymphoma (PCNSL) is a type of non-Hodgkin lymphoma limited to the central nervous system. It has a poor prognosis. Consensus has been reached on the treatment of newly diagnosed patients with high-dose methotrexate-based chemotherapy, but whether the addition of the monoclonal anti-CD20 antibody rituximab improves survival, as it does in systemic B-cell non-Hodgkin lymphoma, remains disputed. In this review, we reflect on the available evidence of the use of rituximab in PCNSL. Whether rituximab has any beneficial effect remains uncertain.
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research